Disease · HP_0002384
Focal impaired awareness seizure
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Focal impaired awareness seizure. Diseases, record HP_0002384. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002384
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Focal impaired awareness seizure
- Open Targets ID
- HP_0002384
- Other names
Complex focal seizures, Complex partial seizure, Complex partial seizures, Dyscognitive seizures, Focal dyscognitive seizure, Focal impaired awareness seizures, Focal seizure with impairment of awareness, Focal seizure with loss of awareness, Focal seizures with impairment of consciousness or awareness, Localised dyscognitive seizure, Localised seizure with impaired awareness, Localised seizure with loss of awareness, Localized dyscognitive seizure, Localized seizure with impaired awareness, Localized seizure with loss of awareness, Partial dyscognitive seizure, Partial seizure with impairment of awareness, Partial seizure with loss of awareness
- Highest stage of its drugs
- Approval, for 5 of its 11 drugs, from TTD
Source Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CENOBAMATE | CHEMBL3989949 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| VIGABATRIN | CHEMBL89598 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| BRIVARACETAM | CHEMBL607400 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ETHOTOIN | CHEMBL1095 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| GABAPENTIN | CHEMBL940 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ESLICARBAZEPINE ACETATE | CHEMBL87992 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LAMOTRIGINE | CHEMBL741 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PERAMPANEL | CHEMBL1214124 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZONISAMIDE | CHEMBL750 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GANAXOLONE | CHEMBL1568698 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets58
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6334 | Drugs and targets |
| SCN9A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/6335 | Drugs and targets |
1 to 10 of 58
See all 58 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00988429 | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures | Phase 3 | 653 | 2014-04-15 | Partial Epilepsy | ESLICARBAZEPINE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT00699582 | To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures | Phase 3 | 389 | 2012-11-22 | Refractory Partial Seizures | PERAMPANEL | Its record names the disease | ClinicalTrials.gov |
| NCT01278173 | A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) | Phase 4 | 65 | 2016-06-07 | Adult Refractory Complex Partial Seizures | VIGABATRIN | Its record names the disease | ClinicalTrials.gov |
| NCT00292461 | A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures | Phase 3 | 64 | 2011-08-15 | Epilepsy | LAMOTRIGINE, ZONISAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03179891 | Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy | Phase 2 | 35 | 2020-09-18 | Epilepsy | DIAZEPAM | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04557085 | Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS | Phase 3 | 519 | Partial Seizure, Focal Seizure | CENOBAMATE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Interictal State (Period A) vs Ictal/Peri-ictal State (Period B): deaths from any cause | 0 of 33 | 0 of 33 | 66 | NCT03179891 | Trial comparisons |
| Interictal State (Period A) vs Ictal/Peri-ictal State (Period B): serious adverse events | 0 of 33 | 1 of 33 | 66 | NCT03179891 | Trial comparisons |
| Zonegran vs Lamotrigine: serious adverse events | 0 of 34 | 1 of 30 | 64 | NCT00292461 | Trial comparisons |
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42975768 | DERIVED | 1 | PubMed |
| 41428177 | DERIVED | 1 | PubMed |
| 41101116 | DERIVED | 1 | PubMed |
| 37059702 | DERIVED | 1 | PubMed |
| 35305920 | DERIVED | 1 | PubMed |
| 33338829 | DERIVED | 1 | PubMed |
| 32801102 | DERIVED | 1 | PubMed |
| 25878175 | DERIVED | 1 | PubMed |
| 25823975 | DERIVED | 1 | PubMed |
| 23663001 | DERIVED | 1 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002384
GET https://conductscience.org/api/diseases/v1/HP_0002384/targets?page=2